December 28,  2015
first country in South America to authorize marketing for dengue vaccine

Following the Mexican government’s approval of Dengvaxia® on December 11 and the Philippines's on December 22 for people aged 9 -45 years living in dengue endemic areas.

Overview of Dengue Vaccines


Since the early 1990s much progress has been made in developing dengue vaccines.  The most advanced candidates include the following approaches:

  • Live attenuated vaccines, prepared through advanced genetic techniques, including chimerization or sequence deletion.
  • Purified inactivated vaccines.
  • Subunit vaccines, which use a portion of the envelope protein of dengue virus.

Other vaccines still in pre-clinical phases of development include plasmid DNA and vectored approaches.